Emerging strategies to target RAS signaling in human cancer therapy
Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant transformation and exhibit malignant phenotypes. The mutational status of RAS correlates with the cl...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2021-07-01
|
| Col·lecció: | Journal of Hematology & Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s13045-021-01127-w |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|